i think we should have more of this in region 4!
spread the news!
ito ang aking diary
ako si BONG
i think we should have more of this in region 4!
spread the news!
ito ang aking diary
ako si BONG
premium derma services for those of us who care so much for our skin
RATES:
MAP:
ako si BONG
ito ang aking diary
"When I did get a chance to connect with others in this madness we sometimes talked about being HIV positive. People would say that they felt the disease was treatable now and that they had a second chance. That seemed to be the general attitude to HIV – that it was no longer a problem for them personally." --- http://www.beigeuk.com/2014/02/chem-sex-revealed-part-one/
nakakalungkot! pero parang nagiging ganito na rin ang sitwasyon dito sa pilipinas... me mga naririnig na akong ganito ang pananaw sa chem sex at pagiging positive kaya wala na silang pakialam. :(
stay safe everyone!
ako si BONG
ito ang aking diary
(photo credits: TRR)
ANDUN AKO
NAKIKIISA
NAGDADALAMHATI PARA SA MGA KAIBIGANG NAUNA NA
NAGPUPUGAY SA MGA KASAMAHANG PATULOY NA NAGPUPUNYAGI
ANDUN AKO
KASAMA NYO
ako si BONG
ito ang aking diary
Bong,
Hi this is kat.. i am a nurse. i got pricked with Hepa B reactive patient through a needle prick injury.. I got tested with baseline diagnostics like HBsAg, Anti-HBs, HCV and HIV Screening tests.. Good thing that I have active titers from Hepatitis B when I was vaccinated in college.. I had negative results from all the labs stated above and had immunity against hepa B.. In this regard, I am being tested again for confirmation, does RITM offer all the above mentioned labs? and wat are the other services they offer? VDRL, etc.. thanks! hope to hear from you.. I hope ur doing fine..
Kat
hello kat,
maraming salamat sa iyong pagsulat, we only offer the following 3 tests at the malate hub FOR FREE: 1. HBsAg (HepaB) 2. SY (Syphillis) 3. HIV Antibody Screening. they have other laboratory tests for other STIs but it's not free, please call them on the numbers noted below for more details:
LOVEYOURSELF HUB (RITM Satellite Clinic Manila)
1850 Leon Guinto St. Malate, Manila.
Tel. 5479334 or 09178351038
Mondays, Thursdays Fridays & Saturdays 11 AM to 7 PM.
(Cut-off at 5:30 PM)
Sunday 9 AM to 4 PM.
(Cut-off at 2 PM)
Tuesdays & Wednesdays Clinic is CLOSED
indeed these needle prick injuries can happen to health workers and we always encourage the practice of universal precaution at all times, at this time and age, safety is always an utmost priority.
i sincerely wish that your retest results would be non-reactive.
ako si BONG
ito ang aking diary
By Jake Wallis Simons (6:30PM BST 27 Apr 2013)
Source: http://www.telegraph.co.uk/health/healthnews/10022664/Scientists-hope-for-HIV-cure.html
Researchers are working on "novel strategies" to find a cure for HIV, with the first results expected “within months”.
Danish scientists are hoping for results that will show that “finding a mass-distributable and affordable cure to HIV is possible”.
They are conducting a clinical trial to test a “novel strategy” in which the HIV virus is "reactivated" from its hiding place within human DNA and potentially destroyed permanently by the immune system.
The move would represent a step forward in the attempt to find a cure for the virus, which causes Aids.
The scientists are currently conducting human trials on their treatment, in the hope of proving that it is effective. It has already been found to work in laboratory tests.
The technique involves unmasking the “reservoirs” formed by the HIV virus inside resting immune cells, bringing it to the surface of the cells. Once it comes to the surface, the body’s natural immune system may be able to kill the virus.
In vitro studies — those that use human cells in a laboratory — of the new technique proved so successful that in January, the Danish Research Council awarded the team 12 million Danish kroner (£1.5 million) to pursue their findings in clinical trials with human subjects.
These are now under way, and according to Dr Ole Søgaard, a senior researcher at the Aarhus University Hospital in Denmark and part of the research team, the early signs are “promising”.
“I am almost certain that we will be successful in activating HIV from the reservoirs," he said.
“The challenge will be getting the patients’ immune system to recognise the virus and destroy it. This depends on the strength and sensitivity of individual immune systems, as well as how large a proportion of the hidden HIV is unmasked.”
Fifteen patients are currently taking part in the trials, and ithe first results from the trial are expected to presented in the second half of 2013.
Dr Søgaard stressed that a cure is not the same as a preventative vaccine, and that raising awareness of unsafe behaviour, including unprotected sex and sharing needles, remains of paramount importance in combating HIV.
With modern HIV treatment, a patient can live an almost normal life, even into old age, with limited side effects.
However, if medication is stopped, HIV reservoirs become active and start to produce more of the virus, meaning that symptoms can reappear within two weeks.
Finding a cure would free a patient from the need to take continuous HIV medication, and save health services billions of pounds.
The technique is being researched in Britain, but studies have not yet moved on to the clinical trial stage. Five universities — Oxford, Cambridge, Imperial College, London, University College, London and King’s College, London — have jointly formed the Collaborative HIV Eradication of Reservoirs UK Biomedical Research Centre group (CHERUB), which is dedicated to finding an HIV cure.
They have applied to the Medical Research Council for funding to conduct clinical trials, which will seek to combine techniques to release the reservoirs of HIV with "immunotherapy", which gives patients a better chance of destroying the virus.
In addition, they are focusing on patients that have only recently been infected, as they believe this will improve chances of a cure. The group hopes to receive a funding decision in May.
“When the first patient is cured in this way it will be a spectacular moment,” says Dr John Frater, a clinical research fellow at the Nuffield School of Medicine, Oxford University, and a member of the CHERUB group.
“It will prove that we are heading in the right direction and demonstrate that a cure is possible. But I think it will be five years before we see a cure that can be offered on a large scale.”
The Danish team’s research is among the most advanced and fast moving in the world, as that they have streamlined the process of putting the latest basic science discoveries into clinical testing.
This means that researchers can progress more quickly to clinical trials, accelerating the process and reaching reliable results sooner than many others.
The technique uses drugs called HDAC Inhibitors, which are more commonly used in treating cancer, to drive out the HIV from a patient’s DNA and onto the surface of infected cells. The Danish researchers are using a particularly powerful type of HDAC inhibitor.
Five years ago, the general consensus was that HIV could not be cured. But then Timothy Ray Brown, an HIV sufferer — who has become known in the field as the Berlin Patient — developed leukaemia.
He had a bone marrow transplant from a donor with a rare genetic mutation that made his cells resistant to HIV. As a result, in 2007 Mr Brown became the first man to ever be fully cured of the disease.
Replicating this procedure on a mass scale is impossible. Nevertheless, the Brown case caused a sea change in research, with scientists focusing on finding a cure as well as suppressing the symptoms.
Two principal approaches are currently being pursued. The first, gene therapy, aims to make a patient’s immune system resistant to HIV. This is complex and expensive, and not easily transferrable to diverse gene pools around the world.
The second approach is the one being pursued by Dr Søgaard and his colleagues in Denmark, the CHERUB group in Britain, and by other laboratories in the United States and Europe.
These are just words but it means a lot for the HIV community!
Lets do away with stigma!
No discrimination!
ako si BONG
Many patients taking HIV drugs can now expect to live into their 70s
Michael Carter
Published: 25 July 2008
A large international study has provided evidence that people taking HIV treatment can now expect to live into their 60s and beyond. The study is published in the July 26th edition of The Lancet, and showed that an individual starting successful HIV treatment aged 20 would be expected to live to be 63, and that a patient initiating an anti-HIV drugs regimen aged 35 could live to the age of 67. It also provided evidence of the dramatic and continued decline in the risk of death amongst people with HIV since effective HIV treatment became available.
What is more, the researchers found that starting treatment with a CD4 cell count above 200 cells/mm3 would mean that a person aged 20 could expect to live to be 70, and that a 35 year-old could survive into their 72nd year.
Nevertheless, they still found that even in their most optimistic estimates, the life-expectancy of HIV-positive individuals was approximately ten years shorter than that of an HIV-negative individual. Furthermore injecting drug users and patients who started HIV treatment with lower CD4 cell counts had lower life-expectancies.
The author of an accompanying editorial calls these findings “exciting” and believes that they underline the importance of prompt diagnosis and treatment of HIV. He also suggests that the risk of death would be diminished and overall prognosis further improved by starting anti-HIV drugs with a CD4 cell count of 500 cells/mm3.
Almost immediately after multi-drug antiretroviral therapy became available in 1996, doctors observed dramatic reductions in rates of illness and death in HIV-positive patients treated with such drugs. A number of studies have shown that antiretroviral therapy has the potential to dramatically improve the prognosis of HIV-positive patients, but they have only considered patients in single cohorts or countries.
Therefore researchers from the Antiretroviral Cohort Collaboration which involves 14 large HIV cohort studies in Canada, Europe and the USA, looked at rates of mortality and the life-expectancy of over 43,000 patients who started HIV treatment for the first time between 1996 – 99, 2000 – 02 and 2002 – 05. They also looked at whether there were any patient characteristics which affected the risk of death or prognosis.
A total of 2056 (5%) patients died. The mortality rate fell from 16 deaths per 1000 person years between 1996- 99 to 10 per 1000 person years between 2002 – 05.
They also noted significant improvements in the prognosis for HIV-positive patients in the ten years of the study. Overall, a 20 year-old starting HIV treatment between 1996 and 2005 would be expected to live another 43 years. Between 1996 and 1999, they calculated that such a patient would live to be 56 years old, but in the period 2002 to 2005 this had improved to a little under 70 years.
There were also impressive improvements in the prognosis of 35 year-olds starting treatment, with an expectation of a further 32 years in life after HIV therapy was initiated. But, once more, prognosis improved over time from an expectation of a further 25 years of life in 1996 – 99, to 32 years by 2002- 05.
Patients who started HIV treatment with a low CD4 cell count (below 100 cells/mm3) had much higher mortality rates than patients initiating antiretroviral therapy with a CD4 cell count above 200 cells/mm3 (aged 20 – 44, 20 per 1000 person years vs. five per 1000 person years).
Furthermore a 20 year-old starting treatment with a CD4 cell count below 100 cells/mm3 would have a life-expectancy of 54 years compared to a life-expectancy of 70 years for a 20 year-old starting treatment with a CD4 cell count above 200 cells/mm3. The importance of CD4 cell count at the time of therapy initiation to prognosis was also seen in 35 year-olds, with patients with a CD4 cell count below 100 cells/mm3 expected to live until they were 62 compared to a prognosis of 72 years for patients with a CD4 cell count above 200 cells/mm3.
The investigators also found that women had a better prognosis than men, but that injecting drug users had a life-expectancy that was up to 20 years shorter than non-injecting drug users.
“There has been an improvement of outcomes with combination antiretroviral therapy between 1996 and 2005, characterised by a marked decrease in mortality rates” write the investigators. They attribute such reductions in mortality and improvements in life-expectancy to “improvements in therapy during the first decade of combination therapy.”
But they note that their study suggests that the prognosis of people taking antiretroviral therapy is still not normal. Picking up on this point, the author of the accompanying editorial highlights the findings of the SMART study which showed that patients with lower CD4 cell counts had a higher risk of serious non-HIV-related illnesses. The SMART study’s conclusions were one of the factors leading to HIV treatment guidelines recommending that antiretroviral therapy should be started at a CD4 cell count of 350 cells/mm3. The author notes the “clinical mischief of untreated HIV infection” and looks forward to the results of a clinical trial which could show if there is any benefit in starting HIV treatment at a CD4 cell count of 500 cells/mm3.
Reference
The Antiretroviral Cohort Collaboration. Life expectancy of individuals on combination therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 372: 293 – 299, 2008.
Cooper DA. Life and death in the cART era. The Lancet 372: 266 – 267, 2008.
Battle Weary: A Poem by River Huston
Is it over yet?
crawling from a foxhole
made in the dirt
thirty years deep
the bodies are piled up
some old as cordwood
other freshly departed
Goodbye Ben
baby honey boy
you texted me
just last night
don't get it bro
but you're in God's hands now
You didn't get the memo?
it gets better, man
but I get it
you just worn out
worn down
How long can you live
with death firmly planted by your side?
it's that way for everyone
but for us it's visible loud
intrusive
bony hand on your shoulder reminding you
of everything you ever done wrong
I manage it
just some days the insides
turn to mud
and i can't get a grip
When the smoke cleared and the artillery
went from heavy mortars
to the occasional sniper fire
you'd think I'd handle it
cause i did the big fights
I survived sister
but it seems to have gotten worse though
when everyone was dying
somehow it was easier
it's that lone warrior
falling when you least expect it
it takes me down every time
This sadness is fierce
grief rolled up like punch
my ghosts
are loud
especially late at night
waking to conversations
long forgotten
My love, my love
how i miss you
Sunrise brings another day
some tea
put on the good face
the sea helps
if it doesn't make me cry
it gets me through another day
____________________________
i heard of a fellow pusit committing suicide a few weeks ago, even after a "self empowerment training" he has undergone --- sad!
ako si BONG
ito ang aking diary
16 new poz friends...
16 enlightening life stories disclosed...
16 more reasons to celebrate life...
with
a more open mind,
a more caring self,
a more loving heart,
and
a brighter and more productive future
ahead of us.
thanks to RITM and DOH!
i feel affirmed
i feel empowered
a great weekend
indeed!
ako si BONG
ito ang aking diary
Layk Kita.
Layk Mo Ako.
Mag Laykan Tayo!
http://www.facebook.com/ako.si.BONG.POZ
more ways to get in touch with me.
ako si BONG